Nucana Plc

Nucana Biomed Limited

Paola Murziani

Christopher McGuigan

Jan Balzarini

Magdalena Slusarczyk

Blanka Gonczy

Christopher Mcguigan

Magdalena Slusarcyzk

Phosphoramidate derivatives of 5-fluoro-2′-deoxyuridine are disclosed for use in the treatment of cancer, especially in the treatment of cancer where the patient shows resistance, for example, in a patient with cells with a lowered level of nucleoside transporter proteins and/or with nucleoside kinase-deficient cells and/or with-infected cells and/or with cells with a raised level of thymidylate synthase.

Phosphoramidate derivatives of 5-fluoro-2′—deoxyuridine for use in the treatment of cancer

Phosphoramidate derivatives of 5-fluoro-2'-deoxyuridine are disclosed for use in the treatment of cancer, especially in the treatment of cancer where the patient shows resistance, for example, in a patient with cells with a lowered level of nucleoside transporter proteins and/or with nucleoside kinase-deficient cells and/or with-infected cells and/or with cells with a raised level of thymidylate synthase.

Phosphoramidate derivatives of 5-fluoro-2'-deoxyuridine for use in the treatment of cancer

Phosphoramidate derivates of 5-fluoro-2'-deoxyuridine are disclosed for use in the treatment of cancer, especially in the treatment of cancer where the patient shows resistance, for example, in a patient with cells with a lowered level of nucleoside transporter proteins and/or with nucleoside kinase-deficient cells and/or with mycoplasma-infected cells and/or with cells with a raised level of thymidylate synthase.

Phosphoramidate derivates of 5-fluoro-2'-deoxyuridine are disclosed for use in the treatment of cancer, especially in the treatment of cancer where the patient shows resistance, for example, in a patient with cells with a lowered level of nucleoside transporter proteins and/or with nucleoside kinase-deficient cells and/or with-infected cells and/or with cells with a raised level of thymidylate synthase.

Phosphoramidate derivatives of 5-fluoro-2'-deoxyuridine are disclosed for use in the treatment of cancer, especially in the treatment of cancer where the patient shows resistance, for example, in a patient with cells with a lowered level of nucleoside transporter proteins and/or with nucleoside kinase-deficient cells and/or with-infected cells and/or with cells with a raised level of thymidylate synthase. 

Phosphoramidate derivatives of 5-fluoro-2'-deoxyuridine are disclosed for use in the treatment of cancer, especially in the treatment of cancer where the patient shows resistance, for example, in a patient with cells with a lowered level of nucleoside transporter proteins and/or with nucleoside kinase-deficient cells and/or with mycoplasma-infected cells and/or with cells with a raised level of thymidylate synthase. 

Growing community of inventors

Cardiff, United Kingdom

Paola Murziani